Clinical trial
A Phase I/II Study of Lenalidomide in Combination With Gemcitabine in Patients…
NCT00179751 · Celgene Corporation, Industry · Terminated
Key facts
| NCT number | NCT00179751 |
|---|---|
| Title | A Phase I/II Study of Lenalidomide in Combination With Gemcitabine in Patients With Untreated Advanced Carcinoma of the Pancreas |
| Official title | A Phase I/II Study Of Lenalidomide (Revlimid ) In Combination With Gemcitabine In Patients With Untreated Advanced Carcinoma Of The Pancreas |
| Lead sponsor | Celgene Corporation, Industry |
| Collaborators | Prologue Research International Industry |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | CC-5013, gemcitabine |
| Enrollment | 50 |
| Start date | Apr 1, 2005 |
| Completion | Aug 1, 2006 |
| First posted | Sep 16, 2005 |
| Last update posted | Nov 7, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: